# Medical Question & Answer

**Sample ID**: ffe8306e-c5a7-416e-a731-5639e419d453
**Dataset Index**: 4634

---

## Question

A 56-year-old man presents with sudden-onset severe eye pain and blurred vision. He says the symptoms onset an hour ago and his vision has progressively worsened. Physical examination reveals a cloudy cornea and decreased visual acuity. Timolol is administered into the eyes to treat this patient's symptoms. Which of the following best describes the mechanism of action of this drug in the treatment of this patient's condition?
A. Increased outflow via dilatation of the uveoscleral veins
B. It suppresses the ciliary epithelium from producing aqueous humor
C. It increases the transit of aqueous humor into the vitreous humor for absorption into the choroid
D. It leads to opening of the trabecular meshwork

---

## Answer

> Let's see… What do we have here? The user is asking which option best describes the mechanism of action of timolol in the treatment of acute angle-closure glaucoma. Let's break this down step-by-step. First, I need to think about the clinical diagnosis and pathophysiology to confirm what timolol is actually treating. Then, I should verify timolol's pharmacologic class and labeled ocular effects. Next, I will examine the evidence for its predominant mechanism versus secondary effects. After that, I need to compare each answer choice against the mechanism data. Finally, I will reconcile any apparent contradictions and select the best answer, making sure the clinical context and references support it.

> Let me first confirm the clinical scenario and pathophysiology. Sudden severe eye pain with a cloudy cornea and declining vision in a mid-dilated, nonreactive pupil strongly suggests acute angle-closure glaucoma, where iridotrabecular apposition blocks aqueous outflow, acutely raising intraocular pressure and threatening the optic nerve; this is an ophthalmic emergency requiring rapid IOP reduction while arranging definitive care, and timolol is a standard first-line agent in this setting [^11417Nn9] [^112wjwsF].

> Wait, let me verify the drug's class and labeled ocular effects. Timolol is a nonselective beta1/beta2-adrenergic antagonist that, when applied topically to the eye, lowers elevated (and normal) intraocular pressure; the onset is typically within 30 minutes with a peak effect at 1–2 hours, which fits the need for rapid IOP control in acute angle closure [^116C8b9s] [^113oVVCa].

> I will now examine the mechanism. The FDA labeling repeatedly states that while the precise ocular hypotensive mechanism is not fully established, tonography and fluorophotometry studies in humans indicate the predominant effect is reduced aqueous humor formation, with some studies showing a slight increase in outflow facility. Importantly, this reduction in production is the primary mechanism clinicians rely on for IOP lowering with timolol [^116C8b9s] [^112vwrWn] [^115C8tpK].

> Hold on, let's not jump to conclusions. I should review the options carefully. Option A claims increased outflow via uveoscleral vein dilation — wait, that sounds like prostaglandin analogs, not timolol; PGAs increase uveoscleral outflow, whereas timolol's main effect is decreased aqueous production, so A is incorrect [^115vxShS] [^112D4ZvE]. Option B states suppression of ciliary epithelium from producing aqueous humor; that aligns with the labeled predominant mechanism of reduced aqueous formation, so B is a strong candidate [^116C8b9s] [^112vwrWn]. Option C proposes increased transit into the vitreous for choroidal absorption — let me reconsider, because there is no evidence that timolol meaningfully redirects aqueous into the vitreous as a therapeutic mechanism, so C is unsupported [^113dHAGd]. Option D suggests opening of the trabecular meshwork; hmm, wait a minute, that's not timolol's primary mechanism either, though a minor increase in outflow facility has been observed in some studies, and agents like pilocarpine or rho-kinase inhibitors more directly modify trabecular outflow, so D overstates timolol's effect and is not the best answer [^116C8b9s] [^115rGWDM] [^116pQVK6].

> But wait, what if I'm overstating that timolol has no outflow effect at all? Let me double-check. The FDA labeling does note that some studies observed a slight increase in outflow facility, yet it explicitly concludes the predominant action is reduced aqueous formation; therefore, while a small outflow effect may exist, it is secondary and not the best description of timolol's mechanism in this context [^116C8b9s] [^112vwrWn].

> I should confirm the clinical relevance in acute angle closure. In AACG, rapid IOP reduction is achieved by decreasing aqueous production with beta-blockers while addressing angle closure with other agents. Guidelines recommend timolol alongside a carbonic anhydrase inhibitor and an alpha-agonist, with pilocarpine given after these to avoid paradoxical pressure rises, reinforcing that timolol's role here is primarily to reduce inflow rather than open the angle or enhance uveoscleral outflow [^11417Nn9] [^112wjwsF].

> Putting this together, the best answer is B, because timolol's predominant and clinically most important mechanism is suppression of aqueous humor production by the ciliary epithelium via beta-adrenergic blockade, which directly lowers IOP in acute angle-closure glaucoma while definitive management is arranged [^116C8b9s] [^112vwrWn] [^11417Nn9].

---

The correct answer is **B. It suppresses the ciliary epithelium from producing aqueous humor**. Timolol is a non-selective beta-blocker that lowers intraocular pressure by **reducing aqueous humor production** at the ciliary body, which is the primary mechanism in acute angle-closure glaucoma [^116C8b9s] [^112vwrWn]. Options A, C, and D are incorrect because timolol does not increase uveoscleral outflow, shift aqueous into the vitreous, or open the trabecular meshwork [^113dHAGd].

---

## Mechanism of action of timolol in acute angle-closure glaucoma

Timolol maleate is a non-selective beta-adrenergic antagonist that **blocks beta-1 and beta-2 receptors** in the ciliary body, thereby reducing aqueous humor production and lowering intraocular pressure (IOP) [^116C8b9s] [^112vwrWn]. This mechanism is especially beneficial in AACG, where IOP rises due to impaired aqueous outflow; by decreasing inflow, timolol helps rapidly lower IOP and prevent optic nerve damage [^11417Nn9].

---

## Clinical evidence supporting the mechanism

Multiple FDA-approved labeling documents and clinical studies consistently state that the **predominant action** of timolol in lowering IOP is through reduced aqueous humor production [^116C8b9s] [^112vwrWn]. Tonography and fluorophotometry studies demonstrate a significant reduction in aqueous formation following timolol administration [^notfound]. Although some studies report a slight increase in outflow facility, this effect is **minor and not the primary mechanism** [^116C8b9s] [^112vwrWn].

---

## Comparison with other options

| **Option** | **Description** | **Correctness** | **Rationale** |
|-|-|-|-|
| A | Increased outflow via dilatation of the uveoscleral veins | Incorrect | Timolol does not significantly increase uveoscleral outflow; prostaglandin analogs (e.g. latanoprost) primarily act via this mechanism [^115vxShS] [^112D4ZvE] |
| B | Suppresses the ciliary epithelium from producing aqueous humor | Correct | This is the primary mechanism supported by clinical evidence and FDA labeling [^116C8b9s] [^112vwrWn] |
| C | Increases transit of aqueous humor into the vitreous humor for absorption into the choroid | Incorrect | There is no evidence that timolol increases aqueous transit into the vitreous humor [^notfound] |
| D | Opens the trabecular meshwork | Incorrect | Timolol does not directly open the trabecular meshwork; this is not a recognized mechanism of action [^notfound] |

---

## Clinical implications and considerations

- **Onset and duration**: Timolol has a rapid onset of action, with IOP reduction detectable within 30 minutes and peak effect at 1–2 hours, providing sustained IOP lowering for up to 24 hours [^116C8b9s] [^113oVVCa].
- **Adjunctive therapy**: Timolol is often used in combination with other medications (e.g. carbonic anhydrase inhibitors, alpha-agonists, miotics) to achieve optimal IOP control in AACG [^11417Nn9] [^112wjwsF].
- **Contraindications**: Caution is advised in patients with reactive airway disease, bradycardia, or heart failure due to systemic beta-blockade effects [^111S9TkY] [^113FJQWu].

---

Timolol lowers IOP in acute angle-closure glaucoma predominantly by **suppressing aqueous humor production** at the ciliary epithelium, making option B the correct answer [^116C8b9s] [^112vwrWn].

---

## References

### Primary open-angle glaucoma preferred practice pattern ® [^115WTaHS]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma PPP — second-generation iStent inject includes two conical implantable stents in a preloaded injector with the same indications as its predecessor; a randomized trial comparing implantation of two iStent inject devices to fixed-combination latanoprost/timolol found comparable efficacy, with modest reductions in IOP and glaucoma medical therapy when combined with cataract surgery versus cataract surgery alone; rare surgical complications include hyphema, stent malposition, and stent obstruction; a 2019 Cochrane Systematic Review found very low quality evidence that the iStent may achieve better IOP control or medication reduction, and selection of iStent or medications should be left to the discretion of the treating ophthalmologist, in consultation with the individual patient (I-, Insufficient Quality, Strong Recommendation).

---

### Brimonidine tartrate, timolol maleate (Combigan) [^117VAwUM]. FDA (2024). Medium credibility.

12.1 Mechanism of Action

COMBIGAN is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

COMBIGAN is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Timolol maleate is a beta1and beta2adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

---

### Dorzolamide hydrochloride and timolol maleate (dorzolamide HCl and timolol maleate) [^113BH8Ug]. FDA (2018). Low credibility.

1 INDICATIONS AND USAGE

Dorzolamide hydrochloride-timolol maleate ophthalmic solution, USP is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of dorzolamide hydrochloride-timolol maleate ophthalmic solution, USP administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14)].

Dorzolamide hydrochloride-timolol maleate ophthalmic solution, USP is a carbonic anhydrase inhibitor with a beta-adrenergic receptor blocking agent indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
The IOP-lowering of dorzolamide hydrochloride-timolol maleate ophthalmic solution, USP twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (1)

---

### Dorzolamide hydrochloride and timolol maleate [^114aQSdB]. FDA (2023). Medium credibility.

Common adverse reactions (1–10%) associated with the use of dorzolamide / timolol OPHTH (also known as Cosopt, Cosopt PF) include: abdominal pain, blepharitis, bronchitis, cataract, conjunctivitis, corneal erosion, cough, dizziness, dry eyes, eye discharge, eyelid erythema, eyelid swelling, foreign body sensation in the eyes, headache, hypertension, indigestion, nasal congestion, nausea, optic disc cupping, pharyngitis, posterior vitreous detachment, recurrent sinusitis, tearing, tremor, upper respiratory tract infections, urinary tract infections and visual field defect.

---

### Timolol maleate [^116AyhCd]. FDA (2020). Medium credibility.

Labeled indications for Timolol maleate (also known as Istalol, Timoptic) include:

- Treatment of hypertension in adults
- Prevention of migraine attacks in adults
- Prevention of cardiovascular mortality in adults with myocardial infarction

---

### Timolol (timolol maleate) [^116C8b9s]. FDA (2022). Medium credibility.

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

Timolol maleate ophthalmic solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of timolol maleate ophthalmic solution can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours, and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of timolol maleate ophthalmic solution is well maintained.

The precise mechanism of the ocular hypotensive action of timolol maleate ophthalmic solution is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

Pharmacokinetics

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of timolol maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

---

### Guidance for incorporating FDA processes into the ACC / AHA clinical practice guideline methodology: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1132qQu8]. Journal of the American College of Cardiology (2025). High credibility.

Hypertension — beta blockers (noncardioselective) include nadolol 40–120 with daily frequency 1, propranolol IR 80–160 with daily frequency 2, and propranolol LA 80–160 with daily frequency 1; avoid use in patients with reactive airways disease and avoid abrupt cessation.

---

### Timolol maleate [^112hM1wZ]. FDA (2020). Medium credibility.

Regarding the use of timolol maleate PO (also known as Istalol, Timoptic) in patients with chronic liver disease, any severity:

- Reduce dose.

---

### Ddorzolamide hydrochloride timolol maleate (Dorzolamide hydrochloride timolol maletae) [^116L6DFD]. FDA (2024). Medium credibility.

1 INDICATIONS & USAGE

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14)].

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (1)

---

### Care of the patient with primary open-angle glaucoma [^1111mYt7]. AOA (2010). Medium credibility.

Strength of Clinical Recommendation Levels — definitions and clinician guidance are as follows: Strong Recommendation states that the benefits clearly exceed the harms and the quality of evidence is excellent (Grade A or B), and "This recommendation should be followed unless a clear and compelling rationale for an alternative approach is present". Recommendation indicates benefits exceed harms but the evidence is not as strong (Grade B or C), and "This recommendation should generally be followed but remain alert for new information". Discretional notes that current evidence is insufficient to assess the balance of benefits and harms, and "There should be an awareness of this recommendation but a flexibility in clinical decision-making, as well as remaining alert for new information".

---

### Timolol maleate (Istalol) [^112qjNjK]. FDA (2024). Medium credibility.

1 INDICATIONS AND USAGE

ISTALOL®is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

ISTALOL is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. (1)

---

### Timolol maleate (Timoptic) [^112yhw2C]. FDA (2022). Medium credibility.

The dosage of timolol maleate OPHTH for treatment of glaucoma in adults (open-angle) is:

- **Start at**: 1 gtt(s) OPHTH BID (0.25%)
- **Maintenance**: 1 gtt(s) OPHTH BID (0.25% or 0.5%)

---

### Care of the patient with primary open-angle glaucoma [^112jcvA8]. AOA (2010). Medium credibility.

Adrenergic agonists — mechanism, agents, and cautions: Adrenergic agonists affect both alpha- and beta-adrenergic receptors, if non-selective, and reduce IOP by both decreasing aqueous formation and resistance at the trabecular meshwork (TM), and brimonidine tartrate and apraclonidine HCL are currently available alpha-adrenergic agonists. Non-selective agents have side effects including rare cardiac arrhythmias, conjunctival injection and cystoid macular edema, and development of pigment spots on the tarsal conjunctiva that limit current usage. Selective alpha-2 receptor agonists are contraindicated in patients taking monoamine oxidase (MAO) inhibitors and in children, may potentiate syndromes associated with vascular insufficiency, and may cause lid retraction, anterior uveitis, fatigue/drowsiness, dizziness and dry nose/mouth, with concerns for allergic (especially follicular) conjunctivitis, dermatitis and tachyphylaxis, especially with use of apraclonidine.

---

### Timolol maleate [^114pYsMh]. FDA (2020). Medium credibility.

Uncommon adverse reactions (less than 1%) associated with the use of timolol maleate PO (also known as Istalol, Timoptic) include: asthenia, bronchospasm, chest pain, decreased libido, dyspepsia, nausea, paresthesia, peripheral edema, rales, syncope, tinnitus and vertigo.

---

### Timolol maleate (Timoptic) [^113oVVCa]. FDA (2022). Medium credibility.

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

TIMOPTIC Ophthalmic Solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of TIMOPTIC can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC is well maintained.

The precise mechanism of the ocular hypotensive action of TIMOPTIC is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

Pharmacokinetics

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

---

### Timolol maleate [^111jhYzV]. FDA (2020). Medium credibility.

Common adverse reactions (1–10%) associated with the use of timolol maleate PO (also known as Istalol, Timoptic) include: bradycardia, cardiac arrhythmias, cold extremities, depression, dizziness, dyspnea, eye irritation, fatigue, headache, pruritus and upper respiratory tract infections.

---

### Dorzolamide hydrochloride and timolol maleate (Cosopt) [^1177tB2t]. FDA (2024). Medium credibility.

1 INDICATIONS AND USAGE

COSOPT®is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14)].

COSOPT is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (1)

---

### Timolol maleate ophthalmic gel forming solution, 0.25% [^1115AU84]. FDA (2025). Medium credibility.

Step 3. Remove the Timolol maleate ophthalmic gel forming solution cap by turning the cap in the direction of the arrows shown (See Figure A). Put the cap in a clean and dry area. Do not let the tip of the bottle touch your fingers or other surfaces.

Step 4. Hold the bottle between your thumb and index finger with 1 hand. Use the index finger of the other hand to pull down the lower eyelid to form a pocket for the eye drop (See Figure B). Tilt your head backwards.

Step 5. Place the tip of the bottle close to your eye. Be careful not to touch your eye with the tip of the bottle. Gently squeeze the bottle and let 1 drop fall into the space between your lower eyelid and your eye (See Figure C). If a drop misses your eye, follow the instructions in steps 4 and 5 again.

Step 6. If your doctor has told you to use Timolol maleate ophthalmic gel forming solution in both eyes, repeat steps 4 and 5 for your other eye.

Step 7. Put the cap back on the bottle and close.

- The Timolol maleate ophthalmic gel forming solution bottle tip is made to give 1 drop at a time. Do not try to make the hole in the tip of your bottle bigger.

---

### Timolol (Betimol) [^115g7M1v]. FDA (2025). Medium credibility.

INDICATIONS AND USAGE

Betimol®is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

---

### Timolol maleate (Timoptic) [^116NBVA8]. FDA (2022). Medium credibility.

Labeled indications for Timolol maleate (also known as Istalol, Timoptic) include:

- Treatment of ocular hypertension in adults
- Treatment of glaucoma in adults (open-angle)

---

### Bimatoprost (Durysta) [^112D4ZvE]. FDA (2024). Medium credibility.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

12.3 Pharmacokinetics

After a single administration of DURYSTA, bimatoprost concentrations were below the lower limit of quantitation (0.001 ng/mL) in the majority (approximately 92%) of patients. The maximum bimatoprost concentration observed in any patient was 0.00224 ng/mL. Bimatoprost acid concentrations were also below the lower limit of quantitation (0.01 ng/mL) in almost all (approximately 99%) of patients.

---

### Timolol maleate ophthalmic gel forming solution, 0.25% [^116kBjt9]. FDA (2025). Medium credibility.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Timolol maleate ophthalmic gel forming solution, when applied topically on the eye, has the action of reducing elevated, as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

The precise mechanism of the ocular hypotensive action of Timolol maleate ophthalmic gel forming solution is not clearly established at this time. Tonography and fluorophotometry studies of TIMOPTIC®(timolol maleate ophthalmic solution) in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

---

### Brimonidine tartrate, timolol maleate (BRIMONIDINE TARTRATE and TIMOLOL MALEATE) [^116onyie]. FDA (2024). Medium credibility.

12.1 Mechanism of Action

Brimonidine tartrate and timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

Brimonidine tartrate and timolol maleate ophthalmic solution is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Timolol maleate is a beta1and beta2adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

---

### Wilderness Medical Society clinical practice guidelines for treatment of eye injuries and illnesses in the wilderness: 2024 update [^11417Nn9]. Wilderness & Environmental Medicine (2024). High credibility.

Acute angle-closure glaucoma (AACG) — recognition, initial treatment, and evacuation: AACG is caused by blockage of aqueous outflow with increased intraocular pressure (IOP), and signs include a nonreactive pupil that is mid-dilated (4 mm to 6 mm) with a taut globe on gentle closed‑lid palpation indicating elevated IOP; AACG is a medical emergency and requires emergent evacuation, with definitive treatment being surgical. If available, the guideline states "we recommend" initiating medical treatment using a beta‑adrenergic antagonist (timolol 0.5%, 1 drop in affected eye 2 times daily), an oral or intravenous carbonic anhydrase inhibitor (acetazolamide, 500 mg 2 times daily), and a topical alpha2‑adrenergic agonist, followed by a topical miotic (pilocarpine 1% to 2%, 1 drop every 15 min for 2 doses) given 1 h after other treatments, and patients should lie flat for at least 1 h. Recommendation ratings are: Medical management — Strong recommendation, moderate‑quality evidence; Surgical management — Strong recommendation, high‑quality evidence; Emergent evacuation — Strong recommendation, low‑quality evidence.

---

### Glaucoma summary benchmarks – 2024 [^116qvXvq]. AAO (2024). High credibility.

Primary open-angle glaucoma suspect — management plan specifies that the goal of treatment is to monitor or lower IOP if an eye is likely to progress to primary open-angle glaucoma (POAG), to monitor for structural changes in optic disc and retina, and to monitor for functional changes of the optic nerve assessing the visual field; the decision to treat may arise in various settings, target IOP is an estimate that must be individualized and/or adjusted, and medical therapy is presently the most common initial intervention to lower IOP with consideration of the balance between side effects and effectiveness. If medical therapy fails to reduce IOP sufficiently, switching to an alternative medication as monotherapy or adding additional medication is appropriate until the desired IOP level is attained.

---

### Care of the patient with primary open-angle glaucoma [^113ssVZh]. AOA (2010). Medium credibility.

Early Manifest Glaucoma Trial (EMGT) — in early, previously untreated open-angle glaucoma, immediate intraocular pressure (IOP) reduction with argon laser trabeculoplasty plus topical betaxolol hydrochloride twice daily significantly delayed progression; patients treated had half of the progression risk of those not receiving treatment (Evidence Grade: A). After a median of eight years of treatment and follow-up, IOP continued to have a marked influence on progression regardless of baseline IOP, and other significant factors included age, bilaterality, exfoliation and DH, with lower systolic perfusion pressure, lower systolic BP and cardiovascular disease history emerging as predictors (Evidence Grade: B).

---

### Travoprost [^1172XQ5h]. FDA (2025). Medium credibility.

Labeled indications for Travoprost (also known as Travatan Z, Idose TR) include:

- Treatment of increased intraocular pressure in adults with chronic open-angle glaucoma

---

### Clinical practice guideline for the management of infantile hemangiomas [^1133kXo4]. Pediatrics (2019). High credibility.

Infantile hemangioma topical timolol (Key Action Statement 3G) — Clinicians may prescribe topical timolol maleate as a therapy for thin and/or superficial IHs (grade B, moderate recommendation). In the AHRQ review, 2 RCTs and 4 cohort studies were included and topical timolol had a mean estimate of expected clearance of 62%; in a multicenter retrospective cohort study of 731 patients, most infants were treated with the 0.5% gel-forming solution and the study revealed improvement in nearly 70% of patients treated for 1 to 3 months. Best responses were observed in thinner superficial IHs (ie, < 1 mm thick); the large majority of infants studied were 6 months or younger at initiation and 41% were ≤ 3 months of age; only 7% required subsequent treatment with a systemic β-blocker. Pending the results of ongoing studies, these factors should lead to caution when using timolol, especially if prescribing more than 1 drop twice daily or when treating preterm or young infants. The AHRQ report emphasized far more reports of harms with oral β-blockers than with timolol but did note 1 report of shortness of breath and insomnia; in the large cohort, adverse events were noted in 3.4% of patients, including local irritation and bronchospasm in 3 patients, with no cardiovascular events and no adverse events significant enough to necessitate drug discontinuation.

---

### Primary open-angle glaucoma suspect preferred practice pattern® guidelines [^112xyrec]. Ophthalmology (2016). Medium credibility.

Primary open-angle glaucoma suspect — medical treatment to lower intraocular pressure (IOP) is outlined as follows: Medical therapy is presently the most common initial intervention to lower IOP, and prostaglandin analogs are the most frequently prescribed because they are the most efficacious and well-tolerated glaucoma medication and need to be instilled only once daily; therefore, prostaglandin analogues are often considered as initial medical therapy unless other factors preclude this. Topical beta adrenergic antagonists are commonly prescribed with good efficacy and tolerability; nonselective agents (e.g., timolol) block both beta-1 and beta-2 receptors, whereas cardioselective beta-blockers (e.g., betaxolol) target beta-1 receptors and minimize, but do not completely eliminate, pulmonary adverse-effect risk in obstructive airway disease. Topical beta-blockers may be dosed once or twice daily, but nighttime dosing is associated with limited efficacy and may contribute to visual field progression via nocturnal reduction of systemic blood pressure. Other glaucoma medications include alpha2 adrenergic agonists, topical and oral carbonic anhydrase inhibitors, rho kinase inhibitors and parasympathomimetics.

---

### Primary open-angle glaucoma suspect preferred practice pattern® guidelines [^113dHAGd]. Ophthalmology (2016). Medium credibility.

Primary open-angle glaucoma suspect — glaucoma medications summarize class mechanisms, intraocular pressure (IOP) reduction, adverse effects, and contraindications as follows. Prostaglandin analogs (Bimatoprost, Latanoprost, Latanoprostene bunod, Tafluprost, Travoprost) increase uveoscleral and/or trabecular outflow with IOP reduction of 25%–33%, with potential side effects such as increased and misdirected eyelash growth and periocular hyperpigmentation, and potential contraindications including macular edema, history of herpetic keratitis, and active uveitis. Beta-adrenergic antagonists (beta-blockers) — nonselective agents Carteolol, Levobunolol, Metipranolol, Timolol and selective Betaxolol — decrease aqueous production with IOP reduction of 20%–25%, with potential side effects including bronchospasm, bradycardia, hypotension, CHF and reduced exercise tolerance, and potential contraindications of chronic obstructive pulmonary disease, asthma, CHF, bradycardia, hypotension, and greater than first-degree heart block. Alpha-adrenergic agonists (Apraclonidine, Brimonidine) decrease aqueous production; decrease episcleral venous pressure or increase uveoscleral outflow with IOP reduction of 20%–25%, with potential side effects including allergic conjunctivitis/contact dermatitis, dry mouth and nose, hypotension, headache, fatigue, and somnolence, and potential contraindications of monoamine oxidase inhibitor therapy and in infants and children. Parasympathomimetic agents — cholinergic agonist Pilocarpine and anticholinesterase agent Echothiophate — increase trabecular outflow with IOP reduction of 20%–25%, with potential side effects such as keratitis, eye or brow ache/pain, and abdominal cramps, and potential contraindications including areas of peripheral retina that predispose to breaks, the need to regularly assess the fundus, and neovascular, uveitic, or malignant glaucoma.

---

### Timolol (Betimol) [^111wiSVQ]. FDA (2025). Medium credibility.

CLINICAL PHARMACOLOGY

Timolol is a non-selective beta-adrenergic antagonist.

It blocks both beta1-and beta2-adrenergic receptors. Timolol does not have significant intrinsic sympathomimetic activity, local anesthetic (membrane-stabilizing) or direct myocardial depressant activity.

Timolol, when applied topically in the eye, reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.

In general, beta-adrenergic blocking agents reduce cardiac output both in healthy subjects and patients with heart diseases. In patients with severe impairment of myocardial function, beta-adrenergic receptor blocking agents may inhibit sympathetic stimulatory effect necessary to maintain adequate cardiac function. In the bronchi and bronchioles, beta-adrenergic receptor blockade may also increase airway resistance because of unopposed parasympathetic activity.

Pharmacokinetics

When given orally, timolol is well absorbed and undergoes considerable first pass metabolism. Timolol and its metabolites are primarily excreted in the urine. The half-life of timolol in plasma is approximately 4 hours.

Clinical Studies

In two controlled multicenter studies in the U.S. Betimol®0.25% and 0.5% were compared with respective timolol maleate eyedrops. In these studies, the efficacy and safety profile of Betimol®was similar to that of timolol maleate.

---

### Timolol maleate (timolol GFS) [^112vwrWn]. FDA (2024). Medium credibility.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Timolol GFS, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. The precise mechanism of the ocular hypotensive action of Timolol GFS is not clearly established at this time. Tonography and fluorophotometry studies of Timolol GFS in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function beta-adrenergic receptor inhibitors may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activities. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

12.2 Pharmacodynamics

Because in some patients the intraocular pressure-lowering response to Timolol GFS may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Timolol GFS. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy can be considered.

12.3 Pharmacokinetics

Following topical ocular administration of timolol to humans, low concentrations of drug are found in plasma. After bilateral administration of a 0.5% timolol maleate solution to healthy volunteers, maximum plasma concentrations were generally below 5 ng/mL. Dosages higher than one drop of 0.5% Timolol GFS once daily have not been studied.

Pharmacokinetic studies in humans using this gel forming solution formulation were not performed. However, systemic uptake from a gel matrix is expected to be slower than from a non-gel forming solution based on studies using other gel forming solutions. The maximum plasma timolol concentration from the gel forming drop is not expected to exceed those of the 0.5% timolol maleate solution.

---

### Care of the patient with primary open-angle glaucoma [^115rGWDM]. AOA (2010). Medium credibility.

Cholinergic agents — mechanism, options, and adverse effects: Cholinergic agents act by stretching the TM, which decreases IOP by increasing trabecular aqueous outflow; available medications include pilocarpine HCL and carbachol, and cholinergics can be used alone or combined with other glaucoma medications. Ocular and systemic side effects include miosis, ciliary muscle spasm (leading to increased myopia and brow-headaches in patients capable of accommodation), stinging and burning, posterior synechiae, narrowed anterior chamber angle, cataract, retinal detachment, bradycardia, bronchospasm, central nervous system depression and gastrointestinal distress, and these side effects and the need for frequent dosing limit current use.

---

### Primary open-angle glaucoma preferred practice pattern ® [^112MRWpb]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma — medication adjustment and combination therapy: "If a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained", and while "fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances", "when the necessary reduction of IOP exceeds the expected efficacy of a single drug, combination therapy may be prescribed in selected patients". The ophthalmologist "should assess the patient for local ocular and systemic side effects and toxicity, including interactions with other medications and potential life-threatening adverse reactions", and patients "should be educated about eyelid closure or nasolacrimal occlusion to reduce systemic absorption after eye drop instillation".

---

### Dorzolamide hydrochloride and timolol maleate [^113MxiYg]. FDA (2023). Medium credibility.

Very common adverse reactions (over 10%) associated with the use of dorzolamide / timolol OPHTH (also known as Cosopt, Cosopt PF) include: blurred vision, change in taste, conjunctival chemosis, eye pain, itchy eyes and superficial punctate keratitis.

---

### Betaxolol hydrochloride (betaxolol) [^116xmdJW]. FDA (2022). Medium credibility.

CLINICAL PHARMACOLOGY

Betaxolol, a cardioselective (beta-1-adrenergic) receptor blocking agent, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.

When instilled in the eye, Betaxolol has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.

Ophthalmic betaxolol (one drop in each eye) was compared to timolol and placebo in a three-way crossover study challenging nine patients with reactive airway disease who were selected on the basis of having at least a 15% reduction in the forced expiratory volume in one second (FEV1) after administration of ophthalmic timolol. Betaxolol had no significant effect on pulmonary function as measured by FEV1, Forced Vital Capacity (FVC) and FEV1/VC. Additionally, the action of Isoproterenol, a beta stimulant administered at the end of the study was not inhibited by ophthalmic betaxolol. In contrast, ophthalmic timolol significantly decreased these pulmonary functions.

No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, three-way crossover study in 24 normal subjects comparing ophthalmic betaxolol, timolol and placebo for effect on blood pressure and heart rate. Mean arterial blood pressure was not affected by any treatment; however, ophthalmic timolol produced a significant decrease in the mean heart rate.

---

### Care of the patient with primary open-angle glaucoma [^114i6bRT]. AOA (2010). Medium credibility.

Ocular surface disease co-treatment — artificial tear osmo-protection — notes that controlling OSD may lead to improved management of glaucoma, and that co-treatment for osmo-protection with an artificial tear solute of 0.5% carboxymethylcellulose and 0.9% glycerin significantly improved the ocular surface of patients taking topical β-blockers or PGAs and improved IOP control.

---

### Primary open-angle glaucoma preferred practice pattern ® [^113AvDFx]. Ophthalmology (2021). High credibility.

Bimatoprost intracameral implant — delivery, efficacy, and safety: In 2020, a bimatoprost intracameral implant received Food and Drug Administration (FDA) approval for patients with ocular hypertension and primary open-angle glaucoma (POAG) and is injected with a 28-gauge delivery system, demonstrating noninferiority to twice daily timolol in phase III clinical trials. In phase I/II studies, a single sustained-release (SR) implant showed similar efficacy to topical bimatoprost 0.03% through 4 months of follow-up, with 68% of patients having a persistent effect at 6 months, and at 24 months central endothelial cell density was comparable between eyes that received the bimatoprost implant and those treated topically.

---

### Timolol maleate [^114GYPAh]. FDA (2020). Medium credibility.

Regarding the use of timolol maleate PO (also known as Istalol, Timoptic) in patients with intermittent hemodialysis:

- Reduce dose. Use with caution.

---

### Questions about generic ophthalmic medications-reaffirmed 2015 [^1155s3QP]. AAO (2015). Medium credibility.

Generic ophthalmic medications — FDA policy and clinical testing requirements indicate that ophthalmic solutions are expected to match the innovator's composition, and studies are required when they do not or when dosage forms are not solutions. Currently, generic ophthalmic solutions, such as latanoprost, are expected to have the same active and inactive ingredients in the same concentrations (both active and inactive), and if they are not the same, then a study comparing the clinical bioequivalence has to be performed. For products that are anything other than a solution, where manufacturing issues could potentially make a difference, the generic has to have a study demonstrating equivalence, even if the actives and inactives are the same. Policy changed over time: Prior to 1992, the FDA used to permit changes in inactive ingredients for ophthalmic generic products without testing, and in 1992, that policy was changed, so it is therefore important to distinguish between old ophthalmic generics (before 1992) and newer ophthalmic generics. For fixed-combination solution products like dorzolamide/timolol with the same active and inactive ingredients in the same concentrations, and without a plausible reason of how the solutions could be different, the FDA generally does not ask for comparative studies; this is in contrast to suspensions, ointments, or emulsions, in which the distribution of particles and milling of the particles (i.e., particle size) can make a difference and therefore the FDA would ask for comparative studies prior to approval of a generic product.

---

### Brimonidine tartrate and timolol maleate [^111LCXd3]. FDA (2025). Medium credibility.

12.1 Mechanism of Action

Brimonidine tartrate and timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

Brimonidine tartrate and timolol maleate ophthalmic solution is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Timolol maleate is a beta1and beta2adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

---

### Betaxolol hydrochloride (betoptic S) [^116TCZQp]. FDA (2025). Medium credibility.

1 INDICATIONS AND USAGE

BETOPTIC S®(betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension.

BETOPTIC S is a beta-adrenergic receptor inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. (1)

---

### Care of the patient with primary open-angle glaucoma [^113jp8Az]. AOA (2010). Medium credibility.

Primary open-angle glaucoma — relative efficacy trials: In both POAG and OH patients, latanoprost, bimatoprost and travoprost are equally effective at lowering IOP, equally well tolerated systemically, but significantly fewer patients reported ocular hyperemia with latanoprost (Evidence Grade: A). Topical latanoprost and bimatoprost produce a statistically significant IOP reduction compared to timolol but are associated with a higher risk of conjunctival hyperemia (Evidence Grade: A). Both bimatoprost .001% and timolol 0.5% lower mean 24hr IOP effectively, but timolol is not as effective in normal IOP control (Evidence Grade: B). Tafluprost had better overall IOP-lowering effect when compared to timolol 0.5% with decreased diurnal IOP and fewer overall adverse events (Evidence Grade: B). Brimonidine provides greater IOP-lowering efficacy than topical CAls as adjunctive therapy to β-blockers or PGAs, and alpha adrenergics, as adjunctive therapy, seem to be better tolerated than CAI adjunctive therapy (Evidence Grade: B).

---

### Primary open-angle glaucoma suspect preferred practice pattern® guidelines [^117MWXSX]. Ophthalmology (2016). Medium credibility.

Primary open-angle glaucoma suspect — breastfeeding considerations state that some topical glaucoma medications, including timolol, carbonic anhydrase inhibitors, and brimonidine, have been detected in breast milk, and the data are controversial as to whether timolol poses a threat to the breastfeeding infant. The American Academy of Pediatrics has approved the use of both oral and topical forms of carbonic anhydrase inhibitors during lactation, although the infant should be carefully monitored when the former are used. Brimonidine is known to cross the blood-brain barrier and can cause apnea and somnolence in infants, toddlers, and children; for this reason, it is generally recommended that the medication not be used in mothers who are breastfeeding.

---

### Brimonidine tartrate and timolol maleate (brimonidine tartrate / timolol maleate ophthalmic solution) [^112KZeyz]. FDA (2025). Medium credibility.

12.1 Mechanism of Action

Brimonidine tartrate/timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

Brimonidine tartrate/timolol maleate ophthalmic solutionis a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Timolol maleate is a beta1and beta2adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

---

### Timolol (timolol maleate) [^1124NfNw]. FDA (2022). Medium credibility.

DOSAGE AND ADMINISTRATION

Preservative-free timolol maleate ophthalmic solution USP, 0.5% is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be guaranteed after the individual unit is opened, the remaining contents should be discarded immediately after administration.

Preservative-free timolol maleate ophthalmic solution is available in concentration of 0.5%. The usual starting dose is one drop of 0.25% preservative-free timolol maleate ophthalmic solution in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) administered twice a day.

Since in some patients the pressure-lowering response to preservative-free timolol maleate ophthalmic solution may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with preservative-free timolol maleate ophthalmic solution.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of 0.5% timolol maleate ophthalmic solution twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives. The concomitant use of two topical beta-adrenergic blocking agents is not recommended (see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents).

---

### Timolol maleate (timolol GFS) [^112T8qrn]. FDA (2024). Medium credibility.

2 DOSAGE AND ADMINISTRATION

Instill one drop of Timolol GFS (either 0.25% or 0.5%) in the affected eye(s) once daily. Shake once before each use.

Timolol GFS may be used alone or in combination with other intraocular pressure lowering medications. Concomitant topical ophthalmic medications should be administered at least 10 minutes before instilling Timolol GFS.

Instill one drop in the affected eye(s) once daily (2).

---

### Timolol maleate (Timoptic) [^117CsHA3]. FDA (2022). Medium credibility.

Very common adverse reactions (over 10%) associated with the use of timolol maleate OPHTH (also known as Istalol, Timoptic) include: burning sensation.

---

### Care of the patient with primary open-angle glaucoma [^115ajezb]. AOA (2010). Medium credibility.

Ophthalmic β-blockers — pulmonary risk and administration: Non-selective β-blockers significantly affect lung function and increase asthma morbidity and should be avoided if better, safer agents are available for these patients (Evidence Grade: A), and the safety of ophthalmic β-blockers can be increased by minimizing systemic absorption (such as by having the patient practice self-punctal occlusion during drop application) (Evidence Grade: D).

---

### Dorzolamide hydrochloride and timolol maleate ophthalmic solution [^113tJVhw]. FDA (2024). Medium credibility.

1 INDICATIONS AND USAGE

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14)].

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is a combination of dorzolamide hydrochloride carbonic anhydrase inhibitor and timolol maleate a beta-adrenergic receptor blocking agent indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (1)

---

### Care of the patient with primary open-angle glaucoma [^117VawBC]. AOA (2010). Medium credibility.

Adrenergic antagonists (beta blockers) — β-blockers act by inhibiting ultrafiltration in the ciliary body, thereby limiting aqueous humor secretion; ophthalmic β-blockers can be non-selective (inhibiting both β1 and β2 receptors) or cardio-selective (inhibiting β1 > β2), with non-selective β-blockers having greater IOP-lowering effects but also more systemic side effects; examples include timolol maleate, levobunolol, metipranolol and betaxolol HCL; ocular side effects usually include dry eye, lid ptosis, conjunctival hyperemia, corneal anesthesia and blurred vision; non-selective β-blockers should be avoided in patients with asthma, chronic obstructive pulmonary disease, atrioventricular block, bradyarrhythmia, unstable congestive heart failure, depression, myasthenia gravis and persons with DM who are prone to hypoglycemic events or patients using calcium channel blockers; β-blockers also reduce the effectiveness of epinephrine used in anaphylactic crisis and should be avoided in patients who might experience such events.

---

### Timolol maleate [^116H8yoj]. FDA (2020). Medium credibility.

Warnings and precautions regarding the use of timolol maleate PO (also known as Istalol, Timoptic):
- **Bronchospasm**: use caution in patients with mild or moderate COPD or bronchospastic disease.
- **Exacerbation of cerebrovascular insufficiency**: use caution in patients with cerebrovascular insufficiency.
- **Exacerbation of muscle weakness**: use caution in patients with myasthenia gravis or myasthenic symptoms.
- **Mask symptoms of hyperthyroidism**: use caution in patients with thyroid disease.
- **Mask symptoms of hypoglycemia**: use caution in patients at risk for hypoglycemia or with diabetes mellitus receiving insulin or oral hypoglycemic agents.
- **Severe hypotension**: use caution in patients undergoing elective surgery.
- **Thyroid storm**: do not discontinue abruptly in patients with thyroid disease suspected of developing thyrotoxicosis.

---

### Dorzolamide hydrochloride and timolol maleate [^113SiKRn]. FDA (2025). Medium credibility.

1 INDICATIONS AND USAGE

Dorzolamide hydrochloride-timolol maleate ophthalmic solution (preservative-free) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of dorzolamide hydrochloride-timolol maleate ophthalmic solution administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14.1)].

Dorzolamide hydrochloride-timolol maleate ophthalmic solution (preservative-free) is a carbonic anhydrase inhibitor with a beta-adrenergic receptor blocking agent indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
The IOP-lowering of dorzolamide hydrochloride-timolol maleate ophthalmic solution twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (1)

---

### Timolol maleate (Timoptic) [^112mcU8k]. FDA (2022). Medium credibility.

Warnings and precautions regarding the use of timolol maleate OPHTH (also known as Istalol, Timoptic):
- **Bronchospasm**: use caution in patients with mild or moderate COPD or bronchospastic disease.
- **Exacerbation of cerebrovascular insufficiency**: use caution in patients with cerebrovascular insufficiency.
- **Exacerbation of ischemic heart disease, myocardial infarction**: do not discontinue abruptly in patients with ischemic heart disease.
- **Exacerbation of muscle weakness**: use caution in patients with myasthenia gravis or myasthenic symptoms.
- **Mask symptoms of hyperthyroidism**: use caution in patients with thyroid disease.
- **Mask symptoms of hypoglycemia**: use caution in patients at risk for hypoglycemia or with diabetes mellitus receiving insulin or oral hypoglycemic agents.
- **Severe hypotension**: use caution in patients undergoing elective surgery.
- **Thyroid storm**: do not discontinue abruptly in patients with thyroid disease suspected of developing thyrotoxicosis.

---

### Timolol maleate (Timoptic) [^113di5FH]. FDA (2022). Medium credibility.

INDICATIONS AND USAGE

TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

---

### Timolol maleate ophthalmic gel forming solution 0.5% [^115C8tpK]. FDA (2023). Medium credibility.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Timolol maleate ophthalmic gel forming solution, when applied topically on the eye, has the action of reducing elevated, as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. The precise mechanism of the ocular hypotensive action of timolol maleate ophthalmic gel forming solution is not clearly established at this time. Tonography and fluorophotometry studies of TIMOPTIC® (timolol maleate ophthalmic solution) in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

---

### Care of the patient with primary open-angle glaucoma [^113n1qVh]. AOA (2010). Medium credibility.

Primary open-angle glaucoma (POAG) medical treatment — topical therapy principles — notes that medical treatment is generally used initially for most forms of POAG and that topical treatment is minimally invasive; however, only 1–7% of the instilled drug reaches the ocular anterior chamber. Start with the medication that provides the least patient risk and most efficacious treatment, considering ocular and systemic side effects, costs, patient preferences and dosage inconvenience. Prostaglandin analogs (PGAs) have been found to provide the best IOP-lowering among all the monotherapy topical drugs, and combining a PGA and another category of topical drug further enhances IOP decrease. Drugs within a glaucoma medication class share similar mechanisms of action and efficacy, and therefore generally can be expected to result in similar IOP reduction; it is usually best to change class or add a medication of a different class to improve therapy, and switching within a class, however, may minimize systemic or local adverse reactions. Combining glaucoma medications (e.g., adding a second and perhaps third drop) to the treatment regimen, usually from different classes, may be beneficial to patients who require a lower intraocular pressure (IOP), but use as few medications as reasonable to decrease toxicity and compliance complexity. If more than one drug is to be topically applied, educate patients to allow time in between drops of at least three to five minutes to allow for proper absorption, and educate patients to avoid touching the bottle tip to the eyes or face, to place just one drop into the inferior cul de sac, and to employ lid and/or nasolacrimal duct closure to enhance drug effectivity while minimizing systemic absorption.

---

### Latanoprostene bunod ophthalmic solution, 0.024% [^1128GQsG]. FDA (2025). Medium credibility.

12.1 Mechanism of Action

Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.

12.2 Pharmacodynamics

Reduction of the intraocular pressure starts approximately 1 to 3 hours after the first administration with the maximum effect reached after 11to13 hours in eyes with elevated intraocular pressure.

---

### Primary open-angle glaucoma suspect preferred practice pattern® guidelines [^115LL7Bx]. Ophthalmology (2016). Medium credibility.

Glaucoma drug delivery systems and intracameral bimatoprost implant — technology and evidence indicate multiple delivery approaches to address adherence and side effects, including punctal plugs, rings placed in the fornix, contact lenses, subconjunctival injections/devices, intracameral delivery systems, and drug-eluting intraocular devices. In 2020, a bimatoprost intracameral implant received FDA approval for ocular hypertension and primary open-angle glaucoma (POAG); this biodegradable implant, injected with a 28-gauge delivery system, demonstrated noninferiority to twice daily timolol in phase III trials. In phase I/II studies, a single bimatoprost sustained-release (SR) implant showed efficacy similar to topical bimatoprost 0.03% through 4 months of follow-up, and 68% of patients had a persistent effect at 6 months.

---

### Timolol maleate (Timoptic) [^112Cujd2]. FDA (2022). Medium credibility.

DOSAGE AND ADMINISTRATION

TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5%. The usual starting dose is one drop of TIMOPTIC 0.25% in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) twice a day.

Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTIC.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of TIMOPTIC 0.5% twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended [see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents].

---

### Timolol maleate ophthalmic (timolol maleate) [^1175smzv]. FDA (2024). Medium credibility.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta1 and beta2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

Timolol maleate ophthalmic solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of timolol maleate ophthalmic solution can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of timolol maleate ophthalmic solution is well maintained.

---

### Dorzolamide hydrochloride and timolol maleate ophthalmic solution [^112sV4ZH]. FDA (2024). Medium credibility.

Dorzolamide hydrochloride and timolol maleate ophthalmic solution may affect the way medicines work, and other medicines may affect how dorzolamide hydrochloride and timolol maleate ophthalmic solution works. Do not start a new medicine without first talking to your healthcare provider.

Ask your healthcare provider or pharmacist for a list of medicines you are using, if you are not sure. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I use dorzolamide hydrochloride and timolol maleate ophthalmic solution?

See the complete Instructions for Use at the end of this Patient Information leaflet for detailed instructions about the right way to use dorzolamide hydrochloride and timolol maleate ophthalmic solution.
Use dorzolamide hydrochloride and timolol maleate ophthalmic solution exactly as your healthcare provider tells you.
Use 1 drop of dorzolamide hydrochloride and timolol maleate ophthalmic solution in the affected eye or both eyes if needed, 2 times each day. 1 drop in the morning and 1 drop in the evening.
If you are using dorzolamide hydrochloride and timolol maleate ophthalmic solution with another eye drop, wait at least 5 minutes before or after using dorzolamide hydrochloride and timolol maleate ophthalmic solution.
If you have eye surgery or have any problems with your eye such as trauma or an infection, talk to your healthcare provider about continuing to use the bottle (multidose) that contains dorzolamide hydrochloride and timolol maleate ophthalmic solution.
Dorzolamide hydrochloride and timolol maleate ophthalmic solution contains a preservative called benzalkonium chloride. The preservative may be absorbed by soft contact lenses. If you wear contact lenses, remove them before using dorzolamide hydrochloride and timolol maleate ophthalmic solution. The lenses can be placed back into your eyes 15 minutes after using dorzolamide hydrochloride and timolol maleate ophthalmic solution.
Do not touch your eye or eyelid with the dropper tip. Eye medicines, not handled the right way, can become contaminated by bacteria that can cause eye infections. Serious damage to the eye and followed by loss of vision may happen from using contaminated eye medicines. If you think your dorzolamide hydrochloride and timolol maleate ophthalmic solution medicine may be contaminated, or if you develop an eye infection, contact your healthcare provider right away about continuing to use your bottle of dorzolamide hydrochloride and timolol maleate ophthalmic solution.
If you use too much dorzolamide hydrochloride and timolol maleate ophthalmic solution you may have dizziness, headaches, shortness of breath, slow heartbeats, or problems breathing. If you have any of these symptoms call your healthcare provider or go to the nearest hospital emergency room right away.

---

### Timolol maleate ophthalmic gel forming solution 0.5% [^117LvHoQ]. FDA (2023). Medium credibility.

Step 3. Remove the timolol maleate ophthalmic gel forming solution cap by turningthe cap in the direction of the arrows shown (See Figure A). Put the cap in a clean and dry area. Do not let the tip of the bottle touch your fingers or other surfaces.

Figure A

Step 4. Hold the bottle between your thumb and index finger with one hand. Use the index finger of the other hand to pull down the lower eyelid to form a pocket for the eye drop (See Figure B). Tilt your head backwards.

Figure B

Step 5. Place the tip of the bottle close to your eye. Be careful not to touch your eye with the tip of the bottle. Gentle sequeeze the bottle and let 1 drop with the tip of the bottle. Gently squeeze the bottle and let 1 drop fall into the space between your lower eyelid and your eye (See Figure C). If a drop misses your eye, follow the instructions in steps 4 and 5 again.

Figure C

Step 6. If your doctor has told you to use timolol maleate ophthalmic gel forming solution in both eyes, repeat steps 4 and 5 for your other eye.

Step 7. Put the cap back on the bottle and close.

The timolol maleate ophthalmic gel forming solution bottle tip is made to give 1 drop at a time. Do not try to make the hole in the tip of your bottle bigger.
Do not wash the bottle tip.
After you have used all of your timolol maleate ophthalmic gel forming solution doses, there will be some timolol maleate ophthalmic gel forming solution left in the bottle. Do not try to remove the extra timolol maleate ophthalmic gel forming solution from the bottle. Throw it away.

---

### Care of the patient with primary open-angle glaucoma [^114jHtka]. AOA (2010). Medium credibility.

Primary open-angle glaucoma (POAG) and ocular hypertension (OH) — prostaglandin analogs (PGAs) should be considered as an initial therapy in patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG), unless contraindicated, with Evidence Quality: Grade A based on Systematic Reviews, Level of Confidence: High, and a Clinical Recommendation Level of Strong Recommendation that should be followed unless clear and compelling rationale for an alternative approach is present. Evidence statements indicate PGAs provide the best intraocular pressure (IOP) lowering among monotherapy topical drugs, combining a PGA with another topical drug category further enhances IOP decrease, and adverse effect incidents should be considered; overall PGAs are more efficacious in lowering IOP at three months than beta-blockers, alpha-agonists, or carbonic anhydrase inhibitors, with bimatoprost, latanoprost and travoprost among the most efficacious and within-class differences small and possibly not clinically meaningful. Potential benefits are preventing and/or minimizing vision loss; potential risks/harms are side effects of medication; benefits significantly outweigh harms; the role of patient preferences is moderate; and gaps in evidence include the need for research on current medical treatments compared with surgery, particularly for people with severe glaucoma and in ethnic groups.

---

### Timolol hemihydrate [^115Pg8gF]. FDA (2024). Medium credibility.

CLINICAL PHARMACOLOGY

Timolol is a non-selective beta-adrenergic antagonist.

It blocks both beta1-and beta2-adrenergic receptors. Timolol does not have significant intrinsic sympathomimetic activity, local anesthetic (membrane-stabilizing) or direct myocardial depressant activity.

Timolol, when applied topically in the eye, reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.

In general, beta-adrenergic blocking agents reduce cardiac output both in healthy subjects and patients with heart diseases. In patients with severe impairment of myocardial function, beta-adrenergic receptor blocking agents may inhibit sympathetic stimulatory effect necessary to maintain adequate cardiac function. In the bronchi and bronchioles, beta-adrenergic receptor blockade may also increase airway resistance because of unopposed parasympathetic activity.

Pharmacokinetics

When given orally, timolol is well absorbed and undergoes considerable first pass metabolism. Timolol and its metabolites are primarily excreted in the urine. The half-life of timolol in plasma is approximately 4 hours.

Clinical Studies

In two controlled multicenter studies in the U.S., timolol ophthalmic solution 0.5% were compared with respective timolol maleate eyedrops. In these studies, the efficacy and safety profile of timolol ophthalmic solution was similar to that of timolol maleate.

---

### 2017 AHA / ACC / HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology / American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society [^116qTCsE]. Circulation (2018). Medium credibility.

2017 VA/SCD guideline antiarrhythmic medications — Table 7 (continued) details dosing, pharmacologic characteristics, and common adverse effects. Metoprolol (II) can be given "IV: 5 mg q 5 min up to 3 doses" or "PO: 25–100 mg" with "Extended release qd or q 12 h"; pharmacology lists "t1/2: 3–4 h" with "Metab: H" and "Excr: U", and adverse effects include "Cardiac: Bradycardia, hypotension, AVB" and "Other: Dizziness, fatigue, diarrhea, depression, dyspnea". Propafenone (IC) dosing is "PO: Immediate release 150–300 mg q 8 h" and "Extended release 225–425 mg q 12 h"; its half-life varies — "t1/2: 2–10 h or 10–32 h t1/2: extensive metabolizers 2–10 h; poor metabolizers 10–32 h" — with "Metab: H" and "Excr: U", and adverse effects are "Cardiac: HF, AVB, drug-induced Brugada syndrome" and "Other: Dizziness, fatigue, nausea, diarrhea, xerostomia, tremor, blurred vision". Propranolol (II) is dosed "IV: 1–3 mg q 5 min to a total of 5 mg", with "PO: Immediate release 10–40 mg q 6 h; Extended release 60–160 mg q 12 h"; pharmacology indicates "t1/2: immediate release 3–6 h" and "Extended release 8–10 h" with "Metab: H" and "Excr: U", and adverse effects include "Cardiac: Bradycardia, hypotension, HF, AVB" and "Other: Sleep disorder, dizziness, nightmares, hyperglycemia, diarrhea, bronchospasm". Sotalol (III) is dosed "IV: 75 mg q 12 h" or "PO: 80–120 mg q 12 h, may increase dose every 3 d; max 320 mg/d"; pharmacology lists "t1/2: 12 h", "Metab: none", and "Excr: U", with common adverse effects "Cardiac: Bradycardia, hypotension, HF, syncope, TdP" and "Other: Fatigue, dizziness, weakness, dyspnea, bronchitis, depression, nausea, diarrhea".

---

### Brimonidine tartrate and timolol maleate (brimonidine tartrate / timolol maleate) [^117Vi5r9]. FDA (2024). Medium credibility.

12.1 Mechanism of Action

Brimonidine tartrate/timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

Brimonidine tartrate/timolol maleate ophthalmic solution is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Timolol maleate is a beta1and beta2adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

---

### Care of the patient with primary open-angle glaucoma [^1157zsLF]. AOA (2010). Medium credibility.

Primary open-angle glaucoma (POAG) — combination products: Concomitant use of several classes of intraocular pressure (IOP)-lowering topical agents may provide synergy, and when dual therapy is indicated, offering a single bottle with multiple active drugs may enhance patient adherence and compliance while decreasing complexity, inconvenience, (preservative) toxicity and perhaps cost (Evidence Grade: D). A brinzolamide 1%/brimonidine 0.2% combination showed good 24hr IOP-lowering efficacy while reducing the treatment burden in patients who require multiple IOP-lowering medications (Evidence Grade: A). A fixed combination of dorzolamide/timolol was found to be both safe and effective in treating NTG (Evidence Grade: B). A fixed combination of latanoprost and netarsudil lowered IOP more than either drug alone (Evidence Grade: D). Non-preserved fixed combination timolol/dorzolamide drops were effective at reducing IOP and better tolerated in benzalkonium chloride (BAK)-sensitive patients than preserved drops (Evidence Grade: B). In patients with POAG and well-controlled IOP, both brimonidine/timolol and dorzolamide/timolol therapies tended to increase OPP and retrobulbar blood flow, with no statistically significant differences between treatments after one month (Evidence Grade: B).

---

### Timolol maleate [^114v9J9a]. FDA (2020). Medium credibility.

Regarding the use of timolol maleate PO (also known as Istalol, Timoptic) in patients with continuous renal replacement:

- Reduce dose. Use with caution.

---

### Betaxolol hydrochloride (betoptic S) [^116b9fCc]. FDA (2025). Medium credibility.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor inhibitor, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic receptor inhibitors reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.

When instilled in the eye, BETOPTIC S has the action of reducing elevated IOP, whether or not accompanied by glaucoma. Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.

Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Betaxolol has the action of reducing elevated as well as normal IOP and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry.

12.2 Pharmacodynamics

The onset of action with betaxolol can generally be noted within 30 minutes and the maximum effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in IOP. In some patients, the IOP lowering responses to BETOPTIC S may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised.

Ophthalmic betaxolol solution at 1% (one drop in each eye) was compared to placebo in a crossover study challenging nine patients with reactive airway disease. Betaxolol HCl had no significant effect on pulmonary function as measured by forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, and was not significantly different from placebo. The action of isoproterenol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol.

No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, crossover study in 24 normal subjects comparing ophthalmic betaxolol and placebo for effects on blood pressure and heart rate.

---

### Bimatoprost [^1162F8MV]. FDA (2025). Medium credibility.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

12.3 Pharmacokinetics

Absorption

After one drop of bimatoprost ophthalmic solution 0.03% was administered once daily to both eyes of 15 healthy subjects for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (0.025 ng/mL) in most subjects within 1.5 hours after dosing. Mean Cmaxand AUC0–24hrvalues were similar on days 7 and 14 at approximately 0.08 ng/mL and 0.09 ng•hr/mL, respectively, indicating that steady state was reached during the first week of ocular dosing. There was no significant systemic drug accumulation over time.

Distribution

Bimatoprost is moderately distributed into body tissues with a steady-state volume of distribution of 0.67 L/kg. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma.

Elimination

Metabolism

Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.

Excretion

Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.

---

### European Glaucoma Society terminology and guidelines for glaucoma, 5th edition [^115Am9cA]. The British Journal of Ophthalmology (2021). High credibility.

Regarding medical management for open-angle glaucoma, more specifically with respect to prostaglandin analogs, EGS 2021 guidelines recommend to initiate prostaglandin analogs as first-line therapy in patients with OAG.

---

### Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [^112xnbVY]. Circulation (2016). Medium credibility.

Table 1 — ophthalmological medications — Topical β-blockers are listed as Major with Level C, mechanism "Negative inotrope", onset "Immediate to intermediate", with the comment "Consider lowering the dose or discontinuing; reversible on discontinuation". Topical cholinergic agents are listed as Minor with Level C, mechanism "Unknown", with onset "Immediate to intermediate".

---

### Timolol maleate (timoptic-XE) [^116tNNdx]. FDA (2022). Medium credibility.

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

TIMOPTIC-XE, when applied topically on the eye, has the action of reducing elevated, as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

The precise mechanism of the ocular hypotensive action of TIMOPTIC-XE is not clearly established at this time. Tonography and fluorophotometry studies of TIMOPTIC®(timolol maleate ophthalmic solution) in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

Pharmacokinetics

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following once daily administration of TIMOPTIC-XE 0.5% in the morning. The mean peak plasma concentration following this morning dose was 0.28 ng/mL.

---

### Timolol maleate ophthalmic (timolol maleate) [^113hWLqj]. FDA (2024). Medium credibility.

INDICATIONS AND USAGE

Timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

---

### Timolol maleate [^115dcftV]. FDA (2020). Medium credibility.

Unknown frequency adverse reactions associated with the use of timolol maleate PO (also known as Istalol, Timoptic) include: anaphylaxis, angina pectoris, arthralgia, AV block, ↓ blood glucose, cough, diarrhea, difficulty concentrating, diplopia, dry eyes, erectile dysfunction, exercise intolerance, hair loss, hallucinations, heart failure, hepatomegaly, hyperpigmentation, hypotension, insomnia, intermittent claudication, limb pain, muscle weakness, nervousness, nightmares, palpitations, ptosis, pulmonary edema, purpura, raynaud's phenomenon, retroperitoneal fibrosis, skin rash, somnolence, stroke, sweating, visual disturbances, vomiting and weight loss.

---

### Primary open-angle glaucoma preferred practice pattern ® [^111S9TkY]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma medical treatment — medical therapy is the most common initial intervention to lower IOP; prostaglandin analogs are the most frequently prescribed because they are efficacious, well tolerated, and instilled once daily, and are often selected as initial therapy unless factors such as contraindications, cost, side effects, intolerance, or patient refusal preclude this. Topical beta adrenergic antagonists are commonly prescribed with good efficacy and tolerability; nonselective agents (e.g., timolol) block both beta-1 and beta-2 receptors, while cardioselective beta-blockers (e.g., betaxolol) target beta-1 receptors and minimize, but do not completely eliminate, pulmonary risk in obstructive airway disease. Topical beta-blockers may be dosed once or twice daily, whereas nighttime dosing is associated with limited efficacy and may contribute to visual field progression via nocturnal reduction of systemic blood pressure. Other options include alpha2 adrenergic agonists, parasympathomimetics, rho-kinase inhibitors, and topical and oral carbonic anhydrase inhibitors.

---

### Primary open-angle glaucoma preferred practice pattern ® [^114x8sem]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma — adjustment of therapy is guided by the following indications: Target intraocular pressure (IOP) is not achieved and the benefits of a change in therapy outweigh the risks for the patient; a patient has progressive optic nerve damage despite achieving the target IOP; the patient is intolerant of the prescribed medical regimen; the patient does not adhere to the prescribed medical regimen; contraindications to individual medicines develop; and when stable optic nerve status and low IOP occur for a prolonged period in a patient taking topical ocular hypotensive agents, a carefully monitored attempt to reduce the medical regimen may be appropriate. Downward adjustment of target pressure can be made in the face of progressive optic disc, imaging, or visual field change. Upward adjustment of target pressure can be considered if the patient has been stable and if the patient either requires (because of side effects) or desires less medication. A follow-up visit in 2 to 8 weeks, depending on disease severity, may help to assess the response and side effects from washout of the old medication or onset of maximum effect of the new medication.

---

### Timolol maleate ophthalmic gel forming solution [^112BNS3b]. FDA (2023). Medium credibility.

Step 3. Remove the Timolol Maleate Ophthalmic Gel Forming Solution cap by turning the cap in the direction of the arrows shown (See Figure A). Put the cap in a clean and dry area. Do not let the tip of the bottle touch your fingers or other surfaces.

Figure A

Step 4. Hold the bottle between your thumb and index finger with 1 hand. Use the index finger of the other hand to pull down the lower eyelid to form a pocket for the eye drop (See Figure B). Tilt your head backwards.

Figure B

Step 5. Place the tip of the bottle close to your eye. Be careful not to touch your eye with the tip of the bottle. Gently squeeze the bottle and let 1 drop fall into the space between your lower eyelid and your eye (See Figure C). If a drop misses your eye, follow the instructions in steps 4 and 5 again.

Figure C

Step 6. If your doctor has told you to use Timolol Maleate Ophthalmic Gel Forming Solution in both eyes, repeat steps 4 and 5 for your other eye.

Step 7. Put the cap back on the bottle and close.

- The Timolol Maleate Ophthalmic Gel Forming Solution bottle tip is made to give 1 drop at a time. Do not try to make the hole in the tip of your bottle bigger.

---

### Primary open-angle glaucoma preferred practice pattern ® [^115vxShS]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma — prostaglandin analogs: Agents Bimatoprost, Latanoprost, Latanoprostene bunod, Tafluprost, and Travoprost increase uveoscleral and/or trabecular outflow with intraocular pressure (IOP) reduction of 25%–33%. Potential side effects include increased and misdirected eyelash growth, periocular hyperpigmentation, conjunctival injection, allergic conjunctivitis/contact dermatitis, keratitis, possible herpes virus activation, increased iris pigmentation, uveitis, cystoid macular edema, periorbitopathy, migraine-like headache, and flu-like symptoms; potential contraindications are macular edema, history of herpetic keratitis, and active uveitis; the FDA pregnancy safety category is C.

---

### Care of the patient with primary open-angle glaucoma [^116pQVK6]. AOA (2010). Medium credibility.

Rho-kinase inhibitors — IOP reduction and tolerability: Rho-kinase inhibitors (e.g., netarsudil) decrease IOP 25% to 30% by decreasing TM resistance (Evidence Grade: D), with local side effects including blurred vision, tearing, conjunctival hyperemia and hemorrhage, cornea haze and verticillate; despite more patients using netarsudil choosing to discontinue treatment due to adverse effects than those using timolol or latanoprost, netarsudil works well with lower IOPs and may have a role in treating NTG (Evidence Grade: D).

---

### Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [^113hXjaL]. Circulation (2016). Medium credibility.

Ophthalmological agents — topical β-blockers and cholinergic agonists in patients with heart failure (HF) — have reported cardiovascular effects. Several case series and reports with topical β-blockers, primarily timolol, describe clinically significant issues in HF including arrhythmias; in 2 HF patients, topical timolol administration led to an exacerbation of HF symptoms, and discontinuation or dose reduction led to rapid resolution of cardiac side effects. Cholinergic agonists, including cholinesterase inhibitors, have been associated with changes in heart rate including atrioventricular block, but this appears uncommon and this class appears to be the least studied.

---

### Wilderness Medical Society practice guidelines for treatment of eye injuries and illnesses in the wilderness [^112wjwsF]. Wilderness & Environmental Medicine (2012). Medium credibility.

Acute angle-closure glaucoma (AACG) — recognition and initial management in the wilderness notes it results from "a blockage of aqueous outflow from the eye resulting in increased intraocular pressure (IOP)" with symptoms including "deep and severe pain, blurry vision, halos around lights, headache, and often nausea and vomiting", and signs such as a "nonreactive pupil that is mid dilated (4 mm to 6 mm)", decreased visual acuity, a "steamy" or "hazy" cornea, and a red eye. Field measurement of IOP is often not possible, but "gentle palpation of the globe through a closed lid may reveal a taut globe indicating elevated IOP". AACG "requires emergent evacuation, as the definitive treatment is surgical". Standard medical therapy includes "timolol 0.5%, 1 drop in affected eye 2 times daily", topical steroids like "prednisolone 1%, 1 drop 4 times daily", and "oral acetazolamide (Diamox), 500 mg 2 times daily", with "Pilocarpine 1% to 2%, 1 drop every 15 minutes for 2 doses" given "1 hour after other treatments", and patients should "lie flat for at least 1 hour". Recommendation labels: "Medical management: 1B", "Surgical management: 1A", and "Emergent evacuation: 1C".

---

### Timolol maleate [^114ywJqU]. FDA (2020). Medium credibility.

Regarding the use of timolol maleate PO (also known as Istalol, Timoptic) in patients with eGFR 0–90 mL/min/1.73 m²:
- Reduce dose. Use with caution.

---

### Care of the patient with primary open-angle glaucoma [^111sJ6i1]. AOA (2010). Medium credibility.

Prostaglandin analogs (PGAs) for POAG — mechanism, efficacy, dosing, and safety — are described as follows: Prostaglandin analogs (PGAs) increase uveo-scleral outflow and decrease IOP about 25% to 30%. Because of generally good IOP-lowering efficacy, limited systemic and ocular side effects, and once-daily dosing at bedtime (HS), PGAs have become "first-line" treatment for many of the glaucomas, and currently available PGAs include bimatoprost, latanoprost, travoprost and tafluprost. Monotherapy with topical travoprost, for example, was shown to consistently control IOP over 24 hours in a significant proportion of POAG patients. Side effects of PGAs can include, but are not limited to, eye color change, darkening of eyelid skin, eyelash growth, ptosis, orbital soft tissue changes, anterior uveitis, cystoid macular edema, stinging, eye redness and itching. A large meta-analysis concluded that overall, PGAs are more efficacious in lowering IOP at three months than beta-blockers, alpha-agonists or carbonic anhydrase inhibitors, and bimatoprost, latanoprost and travoprost are among the most efficacious drugs at lowering IOP, and the within class differences are small and may not be clinically meaningful.

---

### Timolol maleate ophthalmic gel forming solution [^116dFkaU]. FDA (2023). Medium credibility.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta1and beta2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Timolol maleate ophthalmic gel forming solution, when applied topically on the eye, has the action of reducing elevated, as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

The precise mechanism of the ocular hypotensive action of timolol maleate ophthalmic gel forming solution is not clearly established at this time. Tonography and fluorophotometry studies of TIMOPTIC®(timolol maleate ophthalmic solution) in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

---

### Timolol maleate (timolol GFS) [^115ueooU]. FDA (2024). Medium credibility.

1 INDICATIONS AND USAGE

Timolol GFS 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Timolol GFS is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (1).

---

### Dorzolamide hydrochloride and timolol maleate [^112Eq82C]. FDA (2023). Medium credibility.

The dosage of dorzolamide hydrochloride / timolol maleate OPHTH for treatment of glaucoma in adults (open-angle) is 1 gtt(s) OPHTH BID (2%/0.5%)

---

### Glaucoma summary benchmarks – 2024 [^113W9S8S]. AAO (2024). High credibility.

Primary open-angle glaucoma suspect — therapy may be adjusted when target IOP is not achieved and the benefits of a change outweigh the risks, when the patient is intolerant of or does not adhere to the prescribed regimen due to costs or other factors, when new systemic conditions or treatments could contraindicate current therapy, when the patient has been stable for a prolonged period without progression to POAG such that cautious withdrawal of therapy may be considered, or when the patient has converted to POAG.

---

### Care of the patient with primary open-angle glaucoma [^114se9gN]. AOA (2010). Medium credibility.

Primary open-angle glaucoma and ocular hypertension — topical agents timolol and latanoprostene bunod — are described with dosing and comparative effects: Unpreserved timolol gel 0.1% maintained the efficacy of preserved latanoprost drops and reduced intolerance signs and symptoms in almost all OAG or OH patients using preserved latanoprost. Latanoprostene bunod 0.024% dosed once in the evening is well tolerated and is non-inferior to timolol 0.5% used twice a day, results in significantly reduced mean diurnal IOP over three months of treatment in both OAG and OH patients, demonstrated greater IOP-lowering effect throughout the day than timolol used twice a day over three months of treatment, and was found to be safe in adults with POAG and OH.

---

### Timolol maleate (Timoptic) [^112UNghE]. FDA (2022). Medium credibility.

The dosage of timolol maleate OPHTH for treatment of ocular hypertension in adults is:

- **Start at**: 1 gtt(s) OPHTH BID (0.25%)
- **Maintenance**: 1 gtt(s) OPHTH BID (0.25% or 0.5%)

---

### Primary open-angle glaucoma preferred practice pattern ® [^113FJQWu]. Ophthalmology (2021). High credibility.

Primary open-angle glaucoma — beta-adrenergic antagonists (beta-blockers): Nonselective agents Carteolol, Levobunolol, Metipranolol, and Timolol, and selective Betaxolol, decrease aqueous production with IOP reduction of 20%–25%. Potential side effects include allergic conjunctivitis/contact dermatitis, keratitis, bronchospasm, bradycardia, hypotension, CHF, reduced exercise tolerance, depression, and impotence; potential contraindications are chronic obstructive pulmonary disease, asthma, CHF, bradycardia, hypotension, and greater than first-degree heart block; the FDA pregnancy safety category is C.

---

### Dorzolamide hydrochloride and timolol maleate [^111EXizW]. FDA (2023). Medium credibility.

Labeled indications for Dorzolamide / timolol (also known as Cosopt, Cosopt PF) include:

- Treatment of glaucoma in adults (open-angle)
- Treatment of ocular hypertension in adults